Rifampicin

Generic Name: Rifampicin

Brand Names: Isonarif, Rifadin, Rifamate, Rifater, Rofact

Drug Type: Small Molecule

Chemical Formula: C_₄₃H_₅₈N_₄O_₁₂

CAS Number: 13292-46-1

Unique Ingredient Identifier: VJT6J7R4TR

Background: A semisynthetic antibiotic produced from Streptomyces mediterranei. It has a broad antibacterial spectrum, including activity against several forms of Mycobacterium. In susceptible organisms it inhibits DNA-dependent RNA polymerase activity by forming a stable complex with the enzyme. It thus suppresses the initiation of RNA synthesis. Rifampin is bactericidal, and acts on both intracellular and extracellular organisms. (From Gilman et al., Goodman and Gilman's The Pharmacological Basis of Therapeutics, 9th ed, p1160)

Indication: Rifampin is indicated for the treatment of tuberculosis and tuberculosis-related mycobacterial infections. In combination with pyrazinamide and isoniazid, it is used in the initial phase of the short-course treatment of pulmonary tuberculosis.

Associated Conditions: Cholestatic pruritus, MRSA Infections, Prosthetic Joint Infections, Asymptomatic Neisseria meningitidis carrier of the nasopharynx, Initial phase Tuberculosis, Late phase Tuberculosis

Associated Therapies: Antibacterial therapy

Clinical Trials

The Optimal Duration of Preoperative Anti-tuberculosis Treatment of Spinal Tuberculosis

Phase 4

Conditions: Tuberculosis, Spinal

Interventions: Drug: Isoniazid
Drug: Rifampicin
Drug: Ethambutol
Drug: Pyrazinamide

First Posted Date: 2015-06-23

Last Posted Date: 2015-06-23

Lead Sponsor: Beijing Chest Hospital

Target Recruit Count: 400

Registration Number: NCT02477852

Locations: 🇨🇳
Beijing chest hospital, Beijing, Beijing, China

Study in Healthy Male Subjects to Evaluate the Effect of Itraconazole and Rifampicin on the PK of Fedovapagon

Phase 1

Completed

Conditions: Nocturia

Interventions: Drug: fedovapagon
Drug: rifampicin
Drug: Itraconazole

First Posted Date: 2015-05-12

Last Posted Date: 2015-07-30

Lead Sponsor: Vantia Ltd

Target Recruit Count: 29

Registration Number: NCT02440841

Locations: 🇩🇪
PAREXEL Early Phase Clinical Unit Berlin, Berlin, Germany

Understanding The Effect Of A Strong CYP3A4 Inducer On Glasdegib Pharmacokinetics

Phase 1

Completed

Conditions: Healthy Volunteers

Interventions: Drug: Glasdegib
Drug: Rifampin

First Posted Date: 2015-04-30

Last Posted Date: 2015-06-25

Lead Sponsor: Pfizer

Target Recruit Count: 12

Registration Number: NCT02430545

Locations: 🇺🇸
New Haven Clinical Research Unit, New Haven, Connecticut, United States

Effects of Rifampin on the Pharmacokinetics of Ataluren

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: Ataluren
Drug: Rifampin

First Posted Date: 2015-04-06

Last Posted Date: 2017-12-22

Lead Sponsor: PTC Therapeutics

Target Recruit Count: 15

Registration Number: NCT02409004

Locations: 🇨🇦
Inventiv, Quebec, Canada

Whole Blood Bactericidal Activity (WBA) Against Mycobacterium Tuberculosis of Faropenem Plus Amoxicillin/Clavulanic Acid in Healthy Volunteers

Phase 1

Completed

Conditions: Tuberculosis

Interventions: Drug: Rifampicin
Drug: Faropenem
Drug: Amoxicillin/clavulanic acid 500mg/125mg

First Posted Date: 2015-03-19

Last Posted Date: 2017-04-05

Lead Sponsor: National University Hospital, Singapore

Target Recruit Count: 43

Registration Number: NCT02393586

Locations: 🇸🇬
National University Hospital, Singapore, Singapore

Whole Blood Bactericidal Activity (WBA) Against Mycobacterium Tuberculosis of Rifampicin in Healthy Volunteers

Phase 1

Suspended

Conditions: Tuberculosis

Interventions: Drug: Rifampicin

First Posted Date: 2015-03-12

Last Posted Date: 2017-04-13

Lead Sponsor: National University Hospital, Singapore

Target Recruit Count: 18

Registration Number: NCT02387242

Locations: 🇸🇬
National University Hospital, Singapore, Singapore

Trial of Faropenem and Cefadroxil (in Combination With Amoxicillin/Clavulanic Acid and Standard TB Drugs) in Patients With Pulmonary Tuberculosis: Measurement of Early Bactericidal Activity and Effects on Novel Biomarkers

Phase 2

Completed

Conditions: Pulmonary Tuberculosis

Interventions: Drug: Faropenem
Drug: Rifampicin
Drug: Amoxicillin/clavulanic acid
Drug: Cefadroxil

First Posted Date: 2015-03-06

Last Posted Date: 2020-03-23

Lead Sponsor: National University Hospital, Singapore

Target Recruit Count: 58

Registration Number: NCT02381470

Locations: 🇵🇭
Tropical Disease Foundation, Makati City, Philippines
🇵🇭
De La Salle Health Institute, Cavite, Philippines
🇸🇬
National University Hospital, Singapore, Singapore, Singapore

and more 3 locations